Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
-
Published:2024-09
Issue:
Volume:75
Page:102791
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Xing PuyuanORCID,
Wang Shanbing,
Bi Minghong,
Liu Yong,
Zeng Jia,
Wang Xicheng,
Xiao Ke,
Li Weidong,
Guo Jun,
Wang Pu,
Pan Yueyin,
Ren Biyong,
Gao Emei,
Zhang Lei,
Wang Yingchun,
Gan Tianyi,
Cheng Guang,
Shi YuankaiORCID